Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Rutgers Cancer Institute Reports Favorable Safety Profile Seen in Immunotherapy Drug in Aggressive Form of Lung Cancer

8/18/2017

0 Comments

 
New Brunswick, NJ — The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and “promising durable clinical activity” in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease.
 
That is according to data from a phase 1b clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and colleagues at centers around the world. The work appears in the current online edition of the Journal of Clinical Oncology (doi: 10.1200/JCO.2017.72.5069).
 
Janice M. Mehnert, MD, director of the Phase 1/Investigational Therapeutics Program at Rutgers Cancer Institute, associate professor of medicine at Rutgers Robert Wood Johnson Medical School, and senior director on the work said, “Immunotherapy drugs put the body’s natural defenses back to work by targeting the PD-L1 protein and PD-1 receptor and blocking their ability to prevent T cells from destroying cancer cells.”
​“Pembrolizumab has shown anti-tumor activity in advanced malignancies including melanoma and non-small cell lung cancer,” Dr. Mehnert said.  “With treatment options for SCLC patients receiving platinum-based therapies becoming limited when their disease progresses, it is imperative to explore new therapy options for this population.”
 
From March 2014 to May 2015, 157 patients with extensive-stage SCLC were screened from multiple international sites. 
 
Of that number, 24 patients with tumors having a large presence of the PD-L1 protein who were previously treated with platinum-based therapy were enrolled in the trial.
 
Participants received 10mg of pembrolizumab every two weeks for 24 months or until confirmed disease progression or unacceptable toxicity.  Safety, tolerability and response were assessed every eight weeks for the first six months and every 12 weeks thereafter. Median follow-up duration was 9.8 months.
 
Of the evaluable patients, one had a complete response and seven had partial responses for an overall response rate of 33 percent. Sixteen patients (67 percent) experienced treatment related adverse events with the most common being joint pain, rash and lack of energy.
 
Two patients experienced grade three to five adverse events including one with elevated bilirubin.  Another patient experienced weakness, grade-five colitis and reduced blood flow to the intestines.
 
Dr. Mehnert noted, “Our findings show the safety of pembrolizumab in SCLC is consistent with the known safety profile in other tumor types. These results also show pembrolizumab demonstrates promising anti-tumor activity in SCLC patients who received prior treatment and have a large presence of the PD-L1 protein in their tumor.”
 
Building on the findings of this study, a number of clinical trials have been launched at Rutgers Cancer Institute and elsewhere that aim to more accurately define which SCLC patients are more likely to respond to pembrolizumab. 
 
Others aim to explore the safety and efficacy of pembrolizumab when combined with other modes of treatment including chemotherapy, radiation and other immunotherapy regimens.
 
Along with Mehnert, other investigators on the study include Patrick A. Ott, Dana-Farber Cancer Institute; Elena Elez, Vall d’Hebron Institute of Oncology (Spain); Sandrine Hiret, ICO René Gaudcheau (France); Dong-Wan Kim, Seoul National University Hospital (Republic of Korea); Anne Morosky, Sanatan Saraf and Bilal Piperdi, all Merck & Co., Inc. (Kenilworth, New Jersey).
 
This work was supported by Merck & Co., Inc., Kenilworth, New Jersey.
 
About Rutgers Cancer Institute of New Jersey
 
Rutgers Cancer Institute of New Jersey (www.cinj.org) is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center.  As part of Rutgers, The State University of New Jersey, Rutgers Cancer Institute is dedicated to improving the detection, treatment and care of patients with cancer, and to serving as an education resource for cancer prevention both at its flagship New Brunswick location and at its Newark campus at Rutgers Cancer Institute of New Jersey at University Hospital.
 
Physician-scientists across Rutgers Cancer Institute also engage in translational research, transforming their laboratory discoveries into clinical practice that supports patients on both campuses.
 
To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.  Follow us on Facebook at www.facebook.com/TheCINJ.
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
222 West State Street
Suite 302
Trenton, NJ 08608
732-729-9619